Powered by

Celgenerepeatedly raised Revlimid's price to hit aggressive sales targets, congressional probe finds

Sep 30, 2020 - FiercePharma

Pharma has routinely defended its price hikesbyarguing thatresearch is risky and expensive,andrebatesto middlemenare growing.But a congressional probe unveiled Wednesday shows Celgene, now part of Bristol Myers Squibb, had another reason for hiking Revlimid's price: meeting its revenue goals.

Attacked for years over high drug prices, the pharmaceutical industry has routinely defended itselfbyarguing thatresearch is expensiveand risky and thatrebatesto middlemenare growing.

But a cong...